がん遺伝子パネル・がんゲノムプロファイリング市場 - 世界の産業規模、シェア、動向、機会、予測：組織検査別、がんパネルタイプ別、がんタイプ別、用途別、技術別、エンドユーザー別、地域別、競合、2019-2029年

がん遺伝子パネル・がんゲノムプロファイリングの世界市場規模は2023年に99億5,000万米ドルとなり、予測期間では2029年までCAGR 9.43%で着実な成長が予測されています。

世界のがん遺伝子パネル・がんゲノムプロファイリング市場は、精密医療とゲノム技術の進歩に牽引され、著しい成長と変貌を遂げています。この市場は、がんに関連するゲノムの変化を徹底的に分析し、個別化された治療戦略を導くことを中心に展開されています。様々ながん種に関連する遺伝子のセットからなるゲノムがんパネルは、臨床医に患者の腫瘍内の特定の変異、コピー数の変動、その他の遺伝子異常をピンポイントで特定する力を与えます。この情報は、治療法の調整、治療効果の予測、がんの遺伝的基盤の理解に極めて重要です。次世代シーケンシング（NGS）技術は、ハイスループットかつ詳細なゲノムプロファイリングを可能にするものです。市場の拡大には、世界のがん罹患率の上昇が拍車をかけており、正確な診断ツールの必要性が浮き彫りになっています。

人工知能と機械学習の導入により、複雑なゲノムデータの解釈が強化され、より正確で迅速な洞察が容易になります。バイオテクノロジー企業と研究機関のコラボレーションは、技術革新と包括的なゲノムプロファイリングソリューションの創出を促進します。このようなパートナーシップは、がん生物学の理解を進め、新規治療標的の同定に役立ちます。市場はリキッドバイオプシーアプローチへのシフトを目の当たりにしており、がんに関連する遺伝子変化を非侵襲的かつリアルタイムでモニタリングすることを可能にしています。循環腫瘍DNA（ctDNA）の検査などのリキッドバイオプシー技術は、早期発見、治療モニタリング、微小残存病変の評価に貢献します。

さらに、ゲノムデータとトランスクリプトミクス、プロテオミクス、およびその他のオミクス情報を統合するマルチオミクス統合の動向は、がん生物学の全体的な視点を提供します。この統合されたアプローチは、バイオマーカーや潜在的な治療標的の同定を強化し、さまざまながん種の根底にある複雑な分子メカニズムのより徹底した理解を促進します。世界のヘルスケア状況において、個別化治療や標的治療がますます優先される中、市場情勢はさらなる成長を遂げ、正確ながん診断や治療の意思決定のための革新的なソリューションを提供しています。ゲノム技術とその応用の絶え間ない進化は、個別化腫瘍学の時代を推進する市場のダイナミックな性質を強調しています。

主な市場促進要因

ゲノム技術の進歩

がん罹患率の上昇

精密医療への取り組み

主な市場課題

データのプライバシーとセキュリティに関する懸念

包括的データベースへのアクセス制限

主な市場動向

早期発見の重要性の高まり

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のがん遺伝子パネル・がんゲノムプロファイリング市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 組織検査（固形組織検査、液状組織検査）
  • がんパネルタイプ別（単一遺伝子パネル、複数遺伝子パネル）
  • がんタイプ別（肺がん、乳がん、大腸がん、前立腺がん、その他）
  • 用途別（臨床、研究）
  • 技術別（次世代シーケンシング（NGS）、ポリメラーゼ連鎖反応（PCR）、蛍光in-situハイブリダイゼーション（FISH）、免疫組織化学（IHC）、その他）
  • エンドユーザー別（病院、臨床・診断研究所、その他）
  • 地域別
  • 企業別（2023）
• 市場マップ
  • 組織検査別
  • がんパネルタイプ別
  • がんタイプ別
  • 用途別
  • 技術別
  • エンドユーザー別
  • 地域別

第6章 アジア太平洋地域のがん遺伝子パネル・がんゲノムプロファイリング市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 組織検査別
  • がんパネルタイプ別
  • がんタイプ別
  • 用途別
  • 技術別
  • エンドユーザー別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州のがん遺伝子パネル・がんゲノムプロファイリング市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 組織検査別
  • がんパネルタイプ別
  • がんタイプ別
  • 用途別
  • 技術別
  • エンドユーザー別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米のがん遺伝子パネル・がんゲノムプロファイリング市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 組織検査別
  • がんパネルタイプ別
  • がんタイプ別
  • 用途別
  • 技術別
  • エンドユーザー別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米のがん遺伝子パネル・がんゲノムプロファイリング市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 組織検査別
  • がんパネルタイプ別
  • がんタイプ別
  • 用途別
  • 技術別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのがん遺伝子パネル・がんゲノムプロファイリング市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 組織検査別
  • がんパネルタイプ別
  • がんタイプ別
  • 用途別
  • 技術別
  • エンドユーザー別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • エジプト

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界のがん遺伝子パネル・がんゲノムプロファイリング市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Agilent Technologies, Inc.
• ARUP Laboratories Inc
• Burning Rock Biotech Limited
• U.S. Caris MPI, Inc.
• Danaher Corporation
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd
• Fulgent Genetics Inc.
• Illumina, Inc.
• Thermo Fisher Scientific Inc.

第16章 戦略的提言

第17章 調査会社について・免責事項

Global Genomic Cancer Panel & Profiling Market was valued at USD 9.95 billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 9.43% through 2029. The Global Genomic Cancer Panel & Profiling Market is undergoing remarkable growth and transformation, driven by advancements in precision medicine and genomic technologies. This market revolves around the thorough analysis of cancer-related genomic alterations to guide personalized treatment strategies. Genomic cancer panels, which consist of sets of genes associated with various cancer types, empower clinicians to pinpoint specific mutations, copy number variations, and other genetic abnormalities within a patient's tumor. This information is pivotal for tailoring therapies, predicting treatment responses, and comprehending the genetic underpinnings of cancer. Next-Generation Sequencing (NGS) technologies are instrumental, allowing for high-throughput and detailed genomic profiling. The market's expansion is spurred by the escalating global cancer incidence, underscoring the necessity for precise diagnostic tools.

The incorporation of artificial intelligence and machine learning augments the interpretation of intricate genomic data, facilitating more precise and expedited insights. Collaborations between biotechnology firms and research institutions drive innovation and the creation of comprehensive genomic profiling solutions. These partnerships advance the comprehension of cancer biology and aid in identifying novel therapeutic targets. The market witnesses a shift towards liquid biopsy approaches, enabling non-invasive and real-time monitoring of cancer-related genetic alterations. Liquid biopsy techniques, such as the examination of circulating tumor DNA (ctDNA), contribute to early detection, treatment monitoring, and the evaluation of minimal residual disease.

Furthermore, the trend towards multi-omic integration, which merges genomic data with transcriptomics, proteomics, and other -omics information, offers a holistic perspective of cancer biology. This integrated approach enhances the identification of biomarkers and potential therapeutic targets, fostering a more thorough understanding of the complex molecular mechanisms underlying different cancer types. As the global healthcare landscape increasingly prioritizes personalized and targeted therapies, the Genomic Cancer Panel & Profiling Market is poised for further growth, delivering innovative solutions for precise cancer diagnostics and treatment decision-making. The continuous evolution of genomic technologies and their applications underscores the market's dynamic nature in advancing the era of personalized oncology.

Key Market Drivers

Advancements in Genomic Technologies

Advancements in genomic technologies have been instrumental in shaping the landscape of the Global Genomic Cancer Panel & Profiling Market, ushering in a new era of precision medicine. Next-Generation Sequencing (NGS) stands as a cornerstone in these advancements, revolutionizing the speed, efficiency, and depth of genomic analysis. The continuous evolution of NGS platforms has enabled researchers and clinicians to conduct comprehensive genomic profiling with unprecedented accuracy and scale. Improved sequencing speed and reduced costs have made genomic profiling more accessible, allowing for the analysis of a broader range of genes and facilitating a deeper understanding of cancer-related genetic alterations. Beyond NGS, other genomic technologies such as microarray-based platforms and digital PCR contribute valuable insights. Microarrays provide a high-throughput method for simultaneously examining the expression levels of multiple genes, aiding in the identification of biomarkers associated with specific cancers.

Digital PCR offers enhanced sensitivity in detecting rare genetic mutations, contributing to the precision of genomic profiling. The integration of artificial intelligence (AI) and machine learning (ML) has emerged as a transformative force in genomic data interpretation. Advanced algorithms analyze vast datasets, helping identify patterns, predict treatment responses, and discover novel genetic markers. This fusion of genomic technologies and AI not only accelerates the analysis process but also enhances the accuracy of identifying clinically relevant genomic alterations. The advent of single-cell genomics represents another breakthrough, allowing researchers to analyze individual cells within a heterogeneous tumor. This technology unveils the intra-tumor heterogeneity and provides a more nuanced understanding of the genetic diversity present in cancers. These collective advancements empower the Genomic Cancer Panel & Profiling Market to offer more comprehensive and precise insights into the genomic landscape of cancers. As these technologies continue to evolve, the market is poised to witness further refinement in diagnostic accuracy, therapeutic decision-making, and the realization of personalized treatment strategies for cancer patients globally.

Rising Cancer Incidence

The Global Genomic Cancer Panel & Profiling Market is significantly influenced by the alarming and escalating incidence of cancer worldwide. The pervasive rise in cancer cases serves as a driving force behind the increasing adoption of genomic technologies for comprehensive cancer profiling. Cancer remains a leading cause of morbidity and mortality globally, with new cases diagnosed each year reaching staggering numbers. This surge in cancer incidence intensifies the need for precise diagnostic tools that can unravel the intricate genetic underpinnings of various cancer types. Genomic cancer panels play a pivotal role in this scenario by offering a systematic approach to analyze the genetic alterations associated with specific cancers. As the diversity of cancer types expands, so does the demand for tailored genomic profiling solutions. The ability of genomic technologies, such as Next-Generation Sequencing (NGS), to analyze a multitude of genes simultaneously provides clinicians with a comprehensive view of the genomic landscape, aiding in the identification of key mutations, copy number variations, and other genetic abnormalities driving cancer progression.

The rising cancer incidence not only emphasizes the urgency for accurate and early diagnosis but also underscores the importance of personalized treatment strategies. Genomic profiling enables clinicians to identify specific genetic markers that guide the selection of targeted therapies, contributing to more effective and tailored interventions. The exploration of new and emerging biomarkers associated with different cancer types is fueled by the need to understand the molecular intricacies of each case, further amplifying the relevance and demand for genomic cancer panels. In conclusion, the relentless increase in cancer incidence acts as a catalyst for the Global Genomic Cancer Panel & Profiling Market, driving advancements in genomic technologies and fostering a paradigm shift towards precision medicine in the fight against cancer.

Precision Medicine Initiatives

Precision medicine initiatives are playing a pivotal role in shaping the trajectory of the Global Genomic Cancer Panel & Profiling Market, ushering in an era of personalized and targeted therapeutic approaches. These initiatives are driven by the recognition that each patient's cancer is unique, necessitating tailored treatment strategies based on the individual's genetic makeup. Genomic cancer panels stand at the forefront of this paradigm shift, enabling comprehensive analysis of the molecular alterations within a patient's tumor. The core principle of precision medicine is to match specific genomic aberrations with targeted therapies, optimizing treatment outcomes and minimizing adverse effects. As genomic technologies, particularly Next-Generation Sequencing (NGS), become more sophisticated and accessible, precision medicine initiatives gain momentum. Clinicians leverage genomic cancer panels to identify key genetic mutations, copy number variations, and other alterations that drive cancer progression.

This information becomes crucial for making informed decisions about the most effective therapies for a particular patient. These initiatives are often part of large-scale collaborative efforts involving healthcare institutions, research organizations, and biotechnology companies. The goal is to create extensive databases of genomic and clinical data, facilitating a deeper understanding of the genetic basis of cancer and refining treatment strategies. The integration of artificial intelligence and machine learning further enhances the interpretation of vast datasets, assisting clinicians in identifying relevant biomarkers and predicting treatment responses. Precision medicine initiatives contribute to the shift from a one-size-fits-all approach to cancer treatment to a more nuanced and individualized methodology. By aligning treatment plans with the specific genomic profile of each patient's cancer, these initiatives not only improve therapeutic efficacy but also pave the way for future advancements in oncology. The Global Genomic Cancer Panel & Profiling Market is intricately linked to the success and expansion of precision medicine initiatives, as they collectively drive innovation and bring about transformative changes in cancer care.

Key Market Challenges

Data Privacy and Security Concerns

Data privacy and security concerns constitute significant challenges within the Global Genomic Cancer Panel & Profiling Market. The extensive generation, storage, and sharing of genomic data raise crucial issues regarding patient confidentiality and protection. Genomic information is inherently sensitive, encompassing an individual's unique genetic makeup and potential predispositions to various health conditions, including cancer. Securing genomic data from unauthorized access, breaches, or misuse is paramount. The fear of data breaches and the potential misuse of this highly personal information contribute to concerns among patients, healthcare providers, and regulatory bodies.

The need to comply with stringent data protection regulations, such as the Health Insurance Portability and Accountability Act (HIPAA) in the United States or the General Data Protection Regulation (GDPR) in Europe, adds an additional layer of complexity. The challenge lies in establishing robust and standardized security measures to safeguard genomic data throughout its lifecycle-from collection and storage to transmission and analysis. Implementing encryption, access controls, and secure data sharing protocols becomes essential. Striking a balance between facilitating data-driven healthcare advancements and ensuring stringent data privacy safeguards is imperative to foster trust among stakeholders and encourage the widespread adoption of genomic cancer panels. Addressing these concerns is critical to realizing the full potential of genomic data in advancing precision medicine and personalized cancer care.

Limited Access to Comprehensive Databases

Limited access to comprehensive databases poses a significant challenge to the Global Genomic Cancer Panel & Profiling Market. The success of precision medicine relies heavily on vast and diverse datasets that encompass genomic and clinical information from a wide range of populations and cancer types. However, the availability of such comprehensive databases is often constrained. Access to extensive datasets is crucial for identifying patterns, understanding the genetic basis of cancers, and discovering relevant biomarkers that can inform personalized treatment strategies. The challenge arises due to factors like restricted sharing of genomic data, varying data protection regulations, and the lack of standardized data-sharing frameworks. Building inclusive and representative databases becomes particularly challenging for rare cancers and underrepresented populations.

These limitations hinder the ability to draw meaningful conclusions from genomic profiling, potentially leaving gaps in our understanding of the genetic intricacies of certain cancers. Efforts to address this challenge involve fostering collaboration among researchers, healthcare institutions, and biotechnology companies to promote the sharing of data while adhering to ethical and legal considerations. Encouraging open data-sharing practices and establishing frameworks that ensure privacy and security can contribute to overcoming the hurdle of limited access to comprehensive databases, unlocking the full potential of genomic cancer panels in advancing precision oncology.

Key Market Trends

Rising Emphasis on Early Detection

The Global Genomic Cancer Panel & Profiling Market is witnessing a rising emphasis on early detection, marking a transformative shift in cancer care. Genomic cancer panels play a pivotal role in this paradigm by enabling the identification of genetic alterations associated with cancer at its incipient stages. Early detection through genomic profiling allows for the identification of specific biomarkers indicative of cancer predisposition or the presence of minimal residual disease. This emphasis on early detection aligns with the broader goal of intervening in cancer progression at its earliest, most treatable phases. Genomic cancer panels contribute to precision oncology by uncovering genetic signatures that may indicate a predisposition to certain cancers, enabling proactive screening and surveillance strategies.

The identification of actionable mutations early on facilitates the selection of targeted therapies, potentially improving treatment efficacy and patient outcomes. As healthcare systems increasingly recognize the value of early detection in reducing the burden of cancer, the adoption of genomic cancer panels for screening and early intervention is expected to rise, shaping a future where personalized, genomic-driven approaches contribute significantly to cancer prevention and early-stage management.

Segmental Insights

Tissue Testing Insights

Based on Tissue Testing, the Liquid tissue testing emerged as the fastest growing segment in the global genomic cancer panel and profiling market, especially for tissue testing. This trend signifies a shift towards utilizing liquid samples for testing, rather than traditional approaches, which is anticipated to gain prominence in cancer diagnosis and treatment. Liquid biopsy techniques, such as the analysis of circulating tumor DNA (ctDNA), offer non-invasive and real-time monitoring of cancer-related genetic changes. This approach is valuable for early detection, treatment monitoring, and assessing minimal residual disease. As liquid tissue testing continues to gain traction, it is expected to play a crucial role in enhancing our understanding of cancer biology and improving patient outcomes through personalized treatment strategies.

Cancer Type Insights

Based on cancer type, the lung cancer segment dominated the Global Genomic Cancer Panel & Profiling Market in 2023. This is ascribed due to its high prevalence and the critical role of genomic profiling in personalized treatment. As the leading cause of cancer-related deaths, lung cancer demands precise molecular analysis for targeted therapies. Genomic panels help identify specific mutations, guiding clinicians in selecting tailored treatments and improving patient outcomes. The increasing awareness of genomic testing benefits in lung cancer management, coupled with advancements in precision medicine, amplifies the prominence of lung cancer within the Genomic Cancer Panel & Profiling market, emphasizing the significance of genomic insights in optimizing therapeutic strategies for this prevalent and challenging malignancy.

Regional Insights

The dominance of the North America segment in the global Genomic Cancer Panel & Profiling Market is underpinned by several key factors. With a robust healthcare infrastructure and advanced research facilities, the region fosters the widespread adoption of genomic cancer profiling technologies. The presence of leading market players and increased investment in research and development initiatives further contribute to the region's leadership position.

A higher prevalence of cancer cases in North America, combined with a proactive approach towards early detection and personalized medicine, drives the demand for genomic cancer panels. The collaborative efforts among research institutions, pharmaceutical companies, and healthcare providers in the region play a pivotal role in enhancing the market's growth trajectory. These collective endeavors solidify North America's dominant position on the global stage of genomic cancer panel and profiling, shaping the landscape of cancer diagnostics and treatment strategies worldwide.

Key Market Players

Agilent Technologies, Inc

ARUP Laboratories Inc

Burning Rock Biotech Limited

U.S. Caris MPI, Inc.

Danaher Corporation

Exact Sciences Corporation

F. Hoffmann-La Roche Ltd

Fulgent Genetics Inc.

Illumina, Inc.

Thermo Fisher Scientific Inc.

Report Scope:

In this report, the Global Genomic Cancer Panel & Profiling Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Genomic Cancer Panel & Profiling Market, By Tissue Testing:

Solid Tissue Testing Liquid Tissue Testing

Genomic Cancer Panel & Profiling Market, By Cancer Panel Type:

Single-Gene Panel Multi-Gene Panel

Genomic Cancer Panel & Profiling Market, By Cancer Type:

Lung Cancer Breast Cancer Colon Cancer Prostate Cancer Others

Genomic Cancer Panel & Profiling Market, By Application:

Clinical Research

Genomic Cancer Panel & Profiling Market, By Technology:

Next-Generation Sequencing (NGS) Polymerase Chain Reaction (PCR) Fluorescence In-Situ Hybridization (FISH) Immunohistochemistry (IHC) Others

Genomic Cancer Panel & Profiling Market, By End-User:

Hospitals Clinical and Diagnostic Laboratories Others

Genomic Cancer Panel & Profiling Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Genomic Cancer Panel & Profiling Market.

Available Customizations:

Global Genomic Cancer Panel & Profiling Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Genomic Cancer Panel & Profiling Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Tissue Testing (Solid Tissue Testing, Liquid Tissue Testing)
  • 5.2.2. By Cancer Panel Type (Single-Gene Panel, Multi-Gene Panel)
  • 5.2.3. By Cancer Type (Lung Cancer, Breast Cancer, Colon Cancer, Prostate Cancer, Others)
  • 5.2.4. By Application (Clinical, Research)
  • 5.2.5. By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
  • 5.2.6. By End-User (Hospitals, Clinical and Diagnostic Laboratories, Others)
  • 5.2.7. By Region
  • 5.2.8. By Company (2023)
• 5.3. Market Map
  • 5.3.1. By Tissue Testing
  • 5.3.2. By Cancer Panel Type
  • 5.3.3. By Cancer Type
  • 5.3.4. By Application
  • 5.3.5. By Technology
  • 5.3.6. By End-User
  • 5.3.7. By Region

6. Asia Pacific Genomic Cancer Panel & Profiling Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Tissue Testing
  • 6.2.2. By Cancer Panel Type
  • 6.2.3. By Cancer Type
  • 6.2.4. By Application
  • 6.2.5. By Technology
  • 6.2.6. By End-User
  • 6.2.7. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Genomic Cancer Panel & Profiling Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Tissue Testing
      • 6.3.1.2.2. By Cancer Panel Type
      • 6.3.1.2.3. By Cancer Type
      • 6.3.1.2.4. By Application
      • 6.3.1.2.5. By Technology
      • 6.3.1.2.6. By End-User
  • 6.3.2. India Genomic Cancer Panel & Profiling Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Tissue Testing
      • 6.3.2.2.2. By Cancer Panel Type
      • 6.3.2.2.3. By Cancer Type
      • 6.3.2.2.4. By Application
      • 6.3.2.2.5. By Technology
      • 6.3.2.2.6. By End-User
  • 6.3.3. Australia Genomic Cancer Panel & Profiling Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Tissue Testing
      • 6.3.3.2.2. By Cancer Panel Type
      • 6.3.3.2.3. By Cancer Type
      • 6.3.3.2.4. By Application
      • 6.3.3.2.5. By Technology
      • 6.3.3.2.6. By End-User
  • 6.3.4. Japan Genomic Cancer Panel & Profiling Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Tissue Testing
      • 6.3.4.2.2. By Cancer Panel Type
      • 6.3.4.2.3. By Cancer Type
      • 6.3.4.2.4. By Application
      • 6.3.4.2.5. By Technology
      • 6.3.4.2.6. By End-User
  • 6.3.5. South Korea Genomic Cancer Panel & Profiling Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Tissue Testing
      • 6.3.5.2.2. By Cancer Panel Type
      • 6.3.5.2.3. By Cancer Type
      • 6.3.5.2.4. By Application
      • 6.3.5.2.5. By Technology
      • 6.3.5.2.6. By End-User

7. Europe Genomic Cancer Panel & Profiling Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Tissue Testing
  • 7.2.2. By Cancer Panel Type
  • 7.2.3. By Cancer Type
  • 7.2.4. By Application
  • 7.2.5. By Technology
  • 7.2.6. By End-User
  • 7.2.7. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Genomic Cancer Panel & Profiling Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Tissue Testing
      • 7.3.1.2.2. By Cancer Panel Type
      • 7.3.1.2.3. By Cancer Type
      • 7.3.1.2.4. By Application
      • 7.3.1.2.5. By Technology
      • 7.3.1.2.6. By End-User
  • 7.3.2. Germany Genomic Cancer Panel & Profiling Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Tissue Testing
      • 7.3.2.2.2. By Cancer Panel Type
      • 7.3.2.2.3. By Cancer Type
      • 7.3.2.2.4. By Application
      • 7.3.2.2.5. By Technology
      • 7.3.2.2.6. By End-User
  • 7.3.3. Spain Genomic Cancer Panel & Profiling Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Tissue Testing
      • 7.3.3.2.2. By Cancer Panel Type
      • 7.3.3.2.3. By Cancer Type
      • 7.3.3.2.4. By Application
      • 7.3.3.2.5. By Technology
      • 7.3.3.2.6. By End-User
  • 7.3.4. Italy Genomic Cancer Panel & Profiling Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Tissue Testing
      • 7.3.4.2.2. By Cancer Panel Type
      • 7.3.4.2.3. By Cancer Type
      • 7.3.4.2.4. By Application
      • 7.3.4.2.5. By Technology
      • 7.3.4.2.6. By End-User
  • 7.3.5. United Kingdom Genomic Cancer Panel & Profiling Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Tissue Testing
      • 7.3.5.2.2. By Cancer Panel Type
      • 7.3.5.2.3. By Cancer Type
      • 7.3.5.2.4. By Application
      • 7.3.5.2.5. By Technology
      • 7.3.5.2.6. By End-User

8. North America Genomic Cancer Panel & Profiling Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Tissue Testing
  • 8.2.2. By Cancer Panel Type
  • 8.2.3. By Cancer Type
  • 8.2.4. By Application
  • 8.2.5. By Technology
  • 8.2.6. By End-User
  • 8.2.6. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Genomic Cancer Panel & Profiling Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Tissue Testing
      • 8.3.1.2.2. By Cancer Panel Type
      • 8.3.1.2.3. By Cancer Type
      • 8.3.1.2.4. By Application
      • 8.3.1.2.5. By Technology
      • 8.3.1.2.6. By End-User
  • 8.3.2. Mexico Genomic Cancer Panel & Profiling Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Tissue Testing
      • 8.3.2.2.2. By Cancer Panel Type
      • 8.3.2.2.3. By Cancer Type
      • 8.3.2.2.4. By Application
      • 8.3.2.2.5. By Technology
      • 8.3.2.2.6. By End-User
  • 8.3.3. Canada Genomic Cancer Panel & Profiling Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Tissue Testing
      • 8.3.3.2.2. By Cancer Panel Type
      • 8.3.3.2.3. By Cancer Type
      • 8.3.3.2.4. By Application
      • 8.3.3.2.5. By Technology
      • 8.3.3.2.6. By End-User

9. South America Genomic Cancer Panel & Profiling Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Tissue Testing
  • 9.2.2. By Cancer Panel Type
  • 9.2.3. By Cancer Type
  • 9.2.4. By Application
  • 9.2.5. By Technology
  • 9.2.6. By End-User
  • 9.2.7. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Genomic Cancer Panel & Profiling Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Tissue Testing
      • 9.3.1.2.2. By Cancer Panel Type
      • 9.3.1.2.3. By Cancer Type
      • 9.3.1.2.4. By Application
      • 9.3.1.2.5. By Technology
      • 9.3.1.2.6. By End-User
  • 9.3.2. Argentina Genomic Cancer Panel & Profiling Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Tissue Testing
      • 9.3.2.2.2. By Cancer Panel Type
      • 9.3.2.2.3. By Cancer Type
      • 9.3.2.2.4. By Application
      • 9.3.2.2.5. By Technology
      • 9.3.2.2.6. By End-User
  • 9.3.3. Colombia Genomic Cancer Panel & Profiling Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Tissue Testing
      • 9.3.3.2.2. By Cancer Panel Type
      • 9.3.3.2.3. By Cancer Type
      • 9.3.3.2.4. By Application
      • 9.3.3.2.5. By Technology
      • 9.3.3.2.6. By End-User

10. Middle East and Africa Genomic Cancer Panel & Profiling Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Tissue Testing
  • 10.2.2. By Cancer Panel Type
  • 10.2.3. By Cancer Type
  • 10.2.4. By Application
  • 10.2.5. By Technology
  • 10.2.6. By End-User
  • 10.2.7. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Genomic Cancer Panel & Profiling Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Tissue Testing
      • 10.3.1.2.2. By Cancer Panel Type
      • 10.3.1.2.3. By Cancer Type
      • 10.3.1.2.4. By Application
      • 10.3.1.2.5. By Technology
      • 10.3.1.2.6. By End-User
  • 10.3.2. Saudi Arabia Genomic Cancer Panel & Profiling Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Tissue Testing
      • 10.3.2.2.2. By Cancer Panel Type
      • 10.3.2.2.3. By Cancer Type
      • 10.3.2.2.4. By Application
      • 10.3.2.2.5. By Technology
      • 10.3.2.2.6. By End-User
  • 10.3.3. UAE Genomic Cancer Panel & Profiling Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Tissue Testing
      • 10.3.3.2.2. By Cancer Panel Type
      • 10.3.3.2.3. By Cancer Type
      • 10.3.3.2.4. By Application
      • 10.3.3.2.5. By Technology
      • 10.3.3.2.6. By End-User
  • 10.3.4. Egypt Genomic Cancer Panel & Profiling Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Tissue Testing
      • 10.3.4.2.2. By Cancer Panel Type
      • 10.3.4.2.3. By Cancer Type
      • 10.3.4.2.4. By Application
      • 10.3.4.2.5. By Technology
      • 10.3.4.2.6. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Genomic Cancer Panel & Profiling Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Agilent Technologies, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (In case of listed)
  • 15.1.5. Recent Developments
  • 15.1.6. SWOT Analysis
• 15.2. ARUP Laboratories Inc
• 15.3. Burning Rock Biotech Limited
• 15.4. U.S. Caris MPI, Inc.
• 15.5. Danaher Corporation
• 15.6. Exact Sciences Corporation
• 15.7. F. Hoffmann-La Roche Ltd
• 15.8. Fulgent Genetics Inc.
• 15.9. Illumina, Inc.
• 15.10. Thermo Fisher Scientific Inc.

16. Strategic Recommendations

17. About Us & Disclaimer